Menu Search
Equities

Embla Medical hf

0FIW:LSE

Embla Medical hf

Actions
  • Price (DKK)34.70
  • Today's Change34.70 / --
  • Shares traded4.00
  • 1 Year change+26.41%
  • Beta--
Data delayed at least 20 minutes, as of Oct 31 2024 11:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Embla Medical hf, formerly Ossur hf, is an Iceland-based company that operates within the field of medical equipment and supplies sector. The Company is active in the development and distribution of products in the fields of non-invasive prosthetics, medical braces and supports. The Company's business activities are divided into three business segment: The Prosthetics, its product portfolio includes a range of lower and upper limb prosthetic components; The Bracing & Supports, which offers the Unloader One range of knee braces that relieve pain from knee osteoarthritis, as well as the Unloader Hip which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip; and The Patient Care, which operates a network of Patient Care clinics around the world, with each one catering to individual patients and their needs.

  • Revenue in DKK (TTM)5.98bn
  • Net income in DKK491.76m
  • Incorporated1971
  • Employees4.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		EMBLA:CPH since
announced		Transaction
value
FIOR & GENTZ Gesellschaft fuer Entwicklung und Vertrieb von orthopaedietechnischen Systemen mbHDeal completed16 Jan 202416 Jan 2024Deal completed26.41%131.38m
Data delayed at least 15 minutes, as of Nov 22 2024 16:10 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.